SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 19,411.10 |
| Book Value / Share | n/a |
| Price / Book | n/a |
| NCAV ($M) | 15,684.90 |
| NCAV / Share | n/a |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.03 |
| Return on Assets (ROA) | -0.03 |
| Return on Equity (ROE) | -0.03 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.34 |
| Current Ratio | 7.45 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 18,803.50 |
| Assets | 22,529.70 |
| Liabilities | 3,118.60 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2,751.10 |
| Operating Income | -1,314.30 |
| Net Income | -665.30 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 207.70 |
| Cash from Investing | -2,081.20 |
| Cash from Financing | -45.90 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Athos Kg | 42.80 | -1.50 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 200,187 | 559,700 | 35.77 | |
| 252,033 | 571,167 | 44.13 | |
| 232,260 | 899,120 | 25.83 | |
| 346,178 | 1,604,211 | 21.58 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABCL – AbCellera Biologics Inc. | ABOS – Acumen Pharmaceuticals, Inc. |
| ABUS – Arbutus Biopharma Corporation | ACAD – ACADIA Pharmaceuticals Inc. |
| ACLX – Arcellx, Inc. |
Financial data and stock pages provided by
Fintel.io